Stock Scorecard
Stock Summary for Solid Biosciences Inc (SLDB) - $8.51 as of 9/6/2024 3:05:52 PM EST
Total Score
11 out of 30
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for SLDB
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for SLDB
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for SLDB
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 | |
Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for SLDB
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for SLDB
Financial Details for SLDB
Company Overview |
|
---|---|
Ticker | SLDB |
Company Name | Solid Biosciences Inc |
Country | USA |
Description | Solid Biosciences Inc., a life sciences company, is dedicated to developing therapies for Duchenne muscular dystrophy (DMD) in the United States. The company is headquartered in Cambridge, Massachusetts. |
Sector Name | LIFE SCIENCES |
Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
Most Recent Quarter | 6/30/2024 |
Next Earnings Date | 11/6/2024 |
Stock Price History |
|
Last Day Price | 8.51 |
Last Day Price Updated | 9/6/2024 3:05:52 PM EST |
Last Day Volume | 151,249 |
Average Daily Volume | 244,911 |
52-Week High | 15.05 |
52-Week Low | 1.81 |
Last Price to 52 Week Low | 370.17% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 309.61 |
Sector PE | 80.12 |
5-Year Average PE | -2.70 |
Free Cash Flow Ratio | 1.73 |
Industry Free Cash Flow Ratio | 17.61 |
Sector Free Cash Flow Ratio | 30.42 |
Current Ratio Most Recent Quarter | 13.45 |
Total Cash Per Share | 4.93 |
Book Value Per Share Most Recent Quarter | 5.01 |
Price to Book Ratio | 1.70 |
Industry Price to Book Ratio | 10.39 |
Sector Price to Book Ratio | 22.15 |
Price to Sales Ratio Twelve Trailing Months | 3.65 |
Industry Price to Sales Ratio Twelve Trailing Months | 26.85 |
Sector Price to Sales Ratio Twelve Trailing Months | 6.66 |
Share Statistics |
|
Total Shares Outstanding | 38,595,200 |
Market Capitalization | 328,445,152 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Total Years Dividend Increasing | N/A |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | -11.67% |
Reported EPS 12 Trailing Months | -3.14 |
Reported EPS Past Year | -1.25 |
Reported EPS Prior Year | -4.80 |
Net Income Twelve Trailing Months | -90,719,000 |
Net Income Past Year | -96,015,000 |
Net Income Prior Year | -85,981,000 |
Quarterly Revenue Growth YOY | -100.00% |
5-Year Revenue Growth | 0.00% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 190,300,000 |
Total Cash Past Year | 123,640,000 |
Total Cash Prior Year | 213,722,000 |
Net Cash Position Most Recent Quarter | 190,300,000 |
Net Cash Position Past Year | 123,640,000 |
Long Term Debt Past Year | 0 |
Long Term Debt Prior Year | 0 |
Total Debt Most Recent Quarter | 0 |
Equity to Debt Ratio Past Year | 1.00 |
Equity to Debt Ratio Most Recent Quarter | 1.00 |
Total Stockholder Equity Past Year | 126,481,000 |
Total Stockholder Equity Prior Year | 211,666,000 |
Total Stockholder Equity Most Recent Quarter | 193,245,000 |
Free Cash Flow |
|
Free Cash Flow Twelve Trailing Months | -86,287,000 |
Free Cash Flow Per Share Twelve Trailing Months | -2.24 |
Free Cash Flow Past Year | -95,695,000 |
Free Cash Flow Prior Year | -100,992,000 |
Options |
|
Put/Call Ratio | 0.08 |
Has Options | Options Chain |
Liquidity Rating | None |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 0.17 |
MACD Signal | 0.26 |
20-Day Bollinger Lower Band | 5.81 |
20-Day Bollinger Middle Band | 8.25 |
20-Day Bollinger Upper Band | 10.68 |
Beta | 1.92 |
RSI | 48.94 |
50-Day SMA | 7.26 |
150-Day SMA | 9.69 |
200-Day SMA | 24.76 |
System |
|
Modified | 9/7/2024 1:17:19 PM EST |